HAE Haemonetics Corporation logo

HAE Haemonetics Corporation

Healthcare
$65.49+5.73%ClosedMarket Cap: $2.98B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

15.29

PEG

0.44

P/B

3.80

P/S

2.23

EV/EBITDA

11.72

DCF Value

$369.27

FCF Yield

8.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

57.3%

Operating Margin

18.2%

Net Margin

7.3%

ROE

11.3%

ROA

4.1%

ROIC

8.7%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 null$346.4M$-20.1M$
FY null$1.33B$97.3M$
Q3 null$339.0M$44.7M$
Q2 null$327.3M$38.7M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$75.33

Target (Median)

$70.00

Target Range

$67.00 - $89.00

4 Strong Buy4 Buy4 Hold0 Sell0 Strong Sell
B of A SecuritiesBuy
2026-05-22
Barrington ResearchOutperform
2026-05-12
JP MorganNeutral
2026-05-08
MizuhoOutperform
2026-04-13
CitigroupNeutral
2026-03-11

Trading Activity

Insider Trades

View All
Maunsell Farris Maryanneofficer: VP, Chief Accounting Officer
SellTue May 19
Maunsell Farris Maryanneofficer: VP, Chief Accounting Officer
SellTue May 19
Galvin Royofficer: EVP, Chief Commercial Officer
SellTue May 19
Galvin Royofficer: EVP, Chief Commercial Officer
SellTue May 19
DArecca Jamesofficer: EVP, Chief Financial Officer
SellTue May 19

Company Info

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Country

US

Exchange

Beta

0.53

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Peers